secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entrada Therapeutics, Inc. (TRDA)
CIK:        0001689375
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001689375-26-000009
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entrada posts Q4 net loss of $39.2M; cash at $295.7M; DMD program advances
--------------------------------------------------------------------------

- Net loss of $39.2M in Q4 2025 vs net income of $1.1M in Q4 2024; full-year net loss of $143.8M.
- Cash, cash equivalents and marketable securities of $295.7M as of Dec 31, 2025; runway into Q3 2027.
- DMC recommended initiating Cohort 2 of ELEVATE-44-201 at 12 mg/kg; Cohort 1 data expected Q2 2026.
- ELEVATE-45-201 Cohort 1 data on track for mid-2026; ENTR-601-50 regulatory authorization in UK obtained.
- Nomination of ENTR-801 for Usher syndrome type 2A; second ocular candidate expected H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689375/000168937526000009/0001689375-26-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689375/000168937526000009/trda-20260226.htm
  HTML page:      https://secwatch.observer/filing/0001689375-26-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer